Cargando…

Comment on “Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?”

Detalles Bibliográficos
Autores principales:	Di Cesare, Antonella, Maglie, Roberto, Pescitelli, Leonardo, Rosi, Elia, Prignano, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Notes & Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355511/ https://www.ncbi.nlm.nih.gov/pubmed/30740497 http://dx.doi.org/10.1016/j.jdcr.2018.10.011

Ejemplares similares

Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?
por: Capusan, Tania Marusia, et al.
Publicado: (2018)

Severe, ulcerative, lichenoid mucositis associated with secukinumab
por: Thompson, Jordan M., et al.
Publicado: (2016)

Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic
por: Rosi, Elia, et al.
Publicado: (2021)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Clinical and Ultrasonographic Characterization of Hidradenitis Suppurativa in Female Patients: Impact of Early Recognition of the Disease
por: Di Cesare, Antonella, et al.
Publicado: (2023)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Random egg laying in host nests, rather than egg-matching, explains patterns of cuckoo parasitism: a comment on Zhang et al. (2023)
por: Wang, Longwu, et al.
Publicado: (2023)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Changes in metabolic parameters in psoriatic patients treated with secukinumab
por: Wang, Hsuan Ning, et al.
Publicado: (2020)

Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis
por: Kirby, Colm, et al.
Publicado: (2021)

Mind-Personality Relations: Comment on Demetriou et al., 2018
por: Ackerman, Phillip L.
Publicado: (2018)

Comment on Informing relatives of their genetic risk: an examination of the Belgian context
por: de Paor, Aisling
Publicado: (2022)

Tricuspid Regurgitation, Isn't It Time to Look Around the Valve Rather Than the Valve Itself?
por: Lee, Seung-Pyo
Publicado: (2015)

Therapy of PsO in Special Subsets of Patients
por: Di Cesare, Antonella, et al.
Publicado: (2022)

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
por: Smetanova, Jitka, et al.
Publicado: (2022)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Comment on “microRNAs in the Same Clusters Evolve to Coordinately Regulate Functionally Related Genes”
por: Marco, Antonio
Publicado: (2019)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
por: CHELLI, Clara, et al.
Publicado: (2020)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Comment
por: Ring, Tim
Publicado: (2020)

Comment
por: Ring, Tim
Publicado: (2020)

Comment
por: Ring, Tim
Publicado: (2021)

Consistency of Bacterial Triggers in the Pathogenesis of Hidradenitis Suppurativa
por: Rosi, Elia, et al.
Publicado: (2023)

Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509
por: Fusco, Vittorio, et al.
Publicado: (2021)

Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study
por: Damiani, Giovanni, et al.
Publicado: (2019)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2020)

Abrupt Development of Esophageal Candidiasis after Secukinumab Treatment in a Psoriatic Patient
por: Kang, Hyun Jin, et al.
Publicado: (2021)

New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?
por: Obeidat, Adham E, et al.
Publicado: (2021)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?
por: Ramalho, Diogo, et al.
Publicado: (2021)

EDITOR'S COMMENT
por: Vaidya, Rama, et al.
Publicado: (2010)

The psoriatic shift induced by interleukin 17 is promptly reverted by a specific anti-IL-17A agent in a three-dimensional organotypic model of normal human skin culture
por: Donetti, Elena, et al.
Publicado: (2020)

Statin-related Lichenoid Dermatosis: An Uncommon Adverse Reaction to a Common Treatment
por: Vesza, Zsófia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jlt0fmkvk5me64avof3jm694jd